Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: steve kammerer who wrote (339)	1/23/2012 6:13:10 PM
From: tuck	Respond to of 363

Sounds like typical SA optimism, especially wrt a buyout. Nevertheless, holding (been a lonnnggg time) because I think GATTEX will make it to market. Less sure about 558, as it's essentially a repurposed drug. While there's been occasional success with such drugs, I'm skeptical of them. Price targets are a faint reason for buying in and of themselves; one needs to see how they were arrived at. Especially with these "high risk/high reward" companies. Good to see the insider buying though. I haven't looked. I assume it's not new directors buying because they have to. Cheers, Tuck